The detection of cytogenetic abnormalities in multiple myeloma (MM) has received more importance over last years for risk stratification and the new risk-adapted treatment strategies. Conventional G-banding analysis should be included in a routine procedure for the initial diagnostic workup for patients suspected of MM. However, the detection of chromosomal abnormalities in MM by conventional cytogenetics is limited owing to the low proliferative activity of malignant plasma cells as well as the low number of plasma cells in bone marrow specimens. Fluorescence in situ hybridization (FISH) or microarray-based technologies can overcome some of those drawbacks and detect specific target arrangements as well as chromosomal copy number changes. In this review, we will discuss different cytogenetic approaches and compare their strength and weakness to provide genetic information for risk stratification and prediction of outcome in MM patients.
| INTRODUC TI ON
Conventional cytogenetic studies in MM can provide the advantage of whole genome analysis with one experiment.
Abnormal karyotypes are identified in about 30%-50% of MM cases, more often in an advanced stage or a more proliferative form of diseases. However, the low mitotic index, especially in the early stage of diseases, and a difficult interpretation of some cryptic aberrations can be main limiting factors. [4] [5] [6] [7] Fluorescence in situ hybridization (FISH) or microarray-based technologies can overcome some of those drawbacks and detect specific target arrangements as well as chromosomal copy number changes. In this review, we will discuss different cytogenetic approaches and compare their strength and weakness to provide genetic information for risk stratification and prediction of outcome in MM patients.
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| CONVENTIONAL C Y TOG ENE TIC S ( TR ADITIONAL G -BAND K ARYOT YPING)
The detection of chromosomal abnormalities in MM by conventional cytogenetics is limited owing to the low proliferative activity of malignant plasma cells as well as the low number of plasma cells in bone marrow specimens. Clonal chromosomal abnormalities are observed in only 30% of the patients with MM. 10 The addition of interleukin-4 to cultures of bone marrow cells increases the proportion of abnormal metaphases and improves the detection rate of cytogenetic abnormalities to 50%. 11 Despite the low detection rate, abnormal metaphase cells predict adverse prognosis 12 and also provide both numerical and structural information regarding the myeloma clone.
Patients with MM typically show complex karyotypes, with recurrent numerical and structural aberrations. 10, 13, 14 MM can be divided into hyperdiploid and nonhyperdiploid subtypes based on the number of chromosomes. 15 The structural abnormalities include translocations and copy number aberrations such as gains and deletions (Table 1) . 17 In terms of specific trisomies affecting prognosis, trisomies 3 and/or 5 significantly improve overall survival, whereas trisomy 21 is associated with an adverse outcome. 18 Hyperdiploid karyotype group usually has heterogeneous additional-structural-chromosomal aberrations.
| Hyperdiploidy vs Non-hyperdiploidy
| Hyperdiploidy
The median overall survival of patients with hyperdiploid myeloma is negatively correlated with the number of the additional-structuralchromosomal aberrations. 
| Nonhyperdiploidy
Hypodiploid, pseudodiploid, and near-tetraploid karyotypes are referred to as nonhyperdiploid subtypes. Myelomas with either hypodiploidy or pseudodiploidy are characterized by various structural chromosomal abnormalities and monosomies. 
| t(14;20)(q32;q12)
The t(14;20)(q32;q12) translocation is very rare, and it is found in only 1% of the patients with myeloma. 16 This translocation results in the upregulation of the MAFB oncogene and is a high MM risk marker. 3 
| MYC translocation
Translocations involving MYC are a secondary cytogenetic events and occur in 15%-20% of the patients with myeloma. 16 MYC translocation is associated with a poor outcome and has a particularly negative impact in hyperdiploid subgroup.
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| Copy number aberrations
| 1q21 gain
1q21 gain is the most frequent structural abnormality, observed in 35%-40% of the patients with MM. 16 It is represented with duplication of 1q chromosome, unbalanced whole arm translocation of 1q, isochromosomes, or jumping translocation detected by G-banding.
Rearrangements of 1q result from instability of the 1q12 region which is highly decondensed pericentromeric heterochromatin. 31 1q
gain is considered to be a secondary event that influences tumor progression through dosage effect of driver oncogenes such as CKS1B on 1q21. 1q gain is an independent poor prognostic factor.
The number of 1q21 copies is correlated with both disease progression and prognosis. 
| 1p deletion
The deletion of 1p is detected in approximately 30% of the patients with myeloma, 16, 33 and commonly deleted regions have been identified, including 1p32 (CDKN2C), 1p22, and 1p12. The 1p deletion appears to have an adverse impact on clinical outcome. 
| 13q deletion
Around 45%-50% of the patients with myeloma harbor a deletion of the long arm of chromosome 13 of which 85% involve monosomy 13 and the remaining 15% involve interstitial deletions encompassing the minimally deleted region at 13q14.11-13q14.3. 23 The 13q
deletion is rarely observed as a sole anomaly. It is detected in both the hyperdiploid and hypodiploid subtypes but is more frequent in hypodiploidy. Although the 13q deletion is detected in only 10%-20% of the patients by conventional cytogenetics, its detection by metaphase analyses is a critical prognostic factor in myeloma. 12 The results of a study published in 2017 suggest that abnormalities of chromosome 13, for example, monosomy 13 (adverse) and partial deletion of chromosome 13q (protective) show differential effects on overall survival. 34 
| 17p deletion
Chromosome 17p deletion is considered as a secondary event. It is observed in around 10% of patients with newly diagnosed MM, 16, 23 and patients who relapse after treatment have an increased risk of 
| FIS H ANALYS IS
In bone marrow samples of MM patients, the plasma cells are still relatively fewer in number than the other cell types. As such, it is imperative to ensure that testing is performed on the appropriate cell type, particularly in samples with less than 20% plasma cells. which is also compatible with other testing approaches. 40 Given the diagnostic and prognostic significance of translocations involving the IGH locus in MM, FISH is an important component of testing on these samples as some of these translocations are cryptic and cannot be detected by standard chromosome analysis. 40 However, the testing strategy for the detection of these It is thus important to remain alert to the presence of any atypical signal pattern when analyzing MM samples with an IGH break apart, particularly when using this type of probe as first line testing for the detection of IGH rearrangements. However, the cutoffs for these various signal patterns are typically less than 5%.
As for dual color dual fusion probes, the cutoffs for the is not clear if these abnormalities have the same prognostic significance when present at low levels at diagnosis. 48 In both instances, it is important to understand the limitations of the FISH assay when interpreting and reporting the results and to perform reflex testing when appropriate.
| COPY N UMB ER CHANG E BY S NP MICROARR AY
For many years, the standard techniques for identifying genetic Another advantage of microarray testing is that it can be per- 
| Gains
The most common gains for 
| Loss/Deletions
As with FISH, the most common chromosomal losses occur in 1p, and chromosome analysis in myeloma such as 1p and 13q. 8, 53 The most common regions of CN-LOH detected in myeloma are X, 1p, 6q, 8p, 13, 14q, 16q12-q23, and 17 [56] [57] [58] [59] (Table 2 ). have been very few studies related to myeloma. In the few studies utilizing copy number microarray, the most common chromosome regions that have been reported to have oscillating copy number variations are 1q, 14, and 16q, which were associated with a poor outcome. 8, 9 It is highly likely that the consequences of complex Copy number studies with a minimum of 30 patients were included in the table. These studies utilized either SNP microarray or comparative genomic hybridization (aCGH) (does not test for CN-LOH). In these studies, CN-LOH greater than 5-10 Mb was reported, unless the change is known to be clinically significant for myeloma.
TA B L E 2 (Continued)
and function of many genes at once leading to aggressive disease progression. However, the clinical implications of complex copy number changes are limited to only a small number of cases.
Similar changes in other chromosomes may not have the same prognostic indications.
| Conclusions
Multiple 
| CON CLUS I ON AND FUTURE PER S PEC TIVE S
In this report, we have reviewed G-band cytogenetic analysis, FISH, and molecular genetic studies for the genetic characterization of MM patients. This review summarized that cytogenetic evaluation is important for all patients with newly diagnosed MM and includes interphase FISH with enrichment of CD138 + cells especially in samples having less plasma cells. As the published risk stratification algorithms in MM include rearrangements such as t(4;11) and t(14;16) that are best detected by FISH, FISH testing is often the first-tier test performed in clinical laboratories and remains an important part of the cytogenetic workup of MM patients. However, microarraybased genomic profiling is increasingly used to detect copy number alteration throughout the genome, as it is more cost-effective than performing multiple FISH tests for the detection of gains and losses.
Conventional G-banding can also be performed to further characterize the ploidy level and help with the integration of clonal heterogeneity in some patients. The advent of even newer assays such as high throughput sequencing will provide additional diagnostic and prognostic markers for an era of genome-guided target therapies in the near future. In summary, it is important to understand the limitation of each detection technologies. While the next generation sequencing (NGS) is still largely unavailable as a routine laboratory testing, conventional karyotyping, interphase FISH, and microarray analysis will remain for now the most reliable method of cytogenetic profiling in MM patients.
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